MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/falgy.2024.1390813

Медицинская библиотека · Frontiers in allergy · 2024

Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study.

K Mamatha, Aryan Manu Kanjoormana, Prabhakaran Prathibha, Mulakal Johannah Natinga, Das S Syam, Im Krishnakumar, Parameswara Panicker Sreejith

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Allergic rhinitis (AR) is an IgE-mediated reaction to inhaled allergens, and is a prominent health concern affecting approximately 400 million people worldwide. A comprehensive understanding of AR's pathophysiology is imperative for developing novel therapies, especially considering its frequent co-morbidity with asthma and conjunctivitis. The escalating prevalence of AR is correlated with increased urbanization and environmental pollutants, recognized as prominent contributing factors. Dysregulation in immune networks, Th1/Th2 cytokine imbalance, activation of mast cells and eosinophils are implicated in AR progression. Classic AR symptoms include nasal congestion, nasal itching, rhinorrhea, and sneezing which significantly impact the quality of life, social interactions, and workplace productivity.

METHODS

This randomized, double-blind, placebo-controlled, three-arm, three-sequence study was aimed to assess the efficacy of supplementation of a co-delivery form of turmeric extract with ashwagandha extract (CQAB) in comparison with a bioavailable curcumin (CGM) and placebo in alleviating AR symptoms and enhancing the quality of life in individuals with mild AR. Participants received either placebo, CGM, or CQAB twice/day for 28 days, and subjective measures were recorded at the baseline and at the end of study.

RESULTS

CQAB supplementation demonstrated a significant (P < 0.05) improvement in Total Nasal Symptom Score (TNSS) compared to placebo and CGM. Furthermore, CQAB administration resulted in enhanced sleep quality (P < 0.05) as evaluated by the BIS questionnaire, heightened energy levels, and decreased fatigue and overall mood disturbance (POMS-SF) compared to both placebo and CGM.

CONCLUSION

The results suggests that CQAB has the potential to be used as a dietary supplement in alleviating AR discomforts.

CLINICAL TRIAL REGISTRATION: https://ctri.nic.in/Clinicaltrials/login.php; Identifier CTRI/2021/01/030355.

Для цитирования: K Mamatha, Aryan Manu Kanjoormana, Prabhakaran Prathibha, Mulakal Johannah Natinga, Das S Syam, Im Krishnakumar, Parameswara Panicker Sreejith. Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study.. Frontiers in allergy. 2024. DOI: 10.3389/falgy.2024.1390813.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.